Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: cardio-circulatory arrest; respiratory deficit; This is a spontaneous report from a contactable physician downloaded from a regulatory authority-WEB, regulatory authority number IT-MINISAL02-731613. An 86-year-old male patient received the 2nd dose of BNT162b2 (COMIRNATY, Batch: EY7056, Expiry Date: 31Aug2021) via intramuscular route in the right shoulder on 12May2021 at 12:00 as a single dose for COVID-19 immunization. Medical history included hypertensive heart disease, diabetes, glaucoma and allergy to quinolone antibiotics. Concomitant medications included in home therapy with rosuvastatin (CRESTOR), furosemide (LASIX), metformin, glyceryl trinitrate(VENITRIN), and glicazide (DIAMICRON). The patient previously received the first dose of BNT162b2 on 21Apr2021 (Batch: EW2246, Expiry Date: Jul2021) as a single dose for COVID-19 immunization. On 15May2021 the patient entered the emergency room with respiratory deficit, CPR performed with cardiocirculatory arrest. The outcome of cardiocirculatory arrest was fatal, of respiratory deficit was unknown. The patient died on 15May2021. No autopsy was performed. Sender Comment: RLFV_17/05/21: lot, expiration date, administration 1st dose and any suspected adverse reaction; concomitant. pathologies and drugs, clinical report, possible autopsy. A regulatory authority: 19May20/21: dose, posology, indications of use and duration of therapy concomitant Drugs, clinical report Reporter comment: Patient enters the emergency room with respiratory deficit. Stops circulatory cardio; Reporter''s Comments: Patient enters the emergency room with respiratory deficit. Stops circulatory cardio; Reported Cause(s) of Death: cardio-circulatory arrest
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166